-
Dec 2013
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
Lancet Diabetes EndocrinolRigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR, T1DAL Study Team. -
Nov 2013
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
DiabetesHerold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, AbATE Study Team. -
Oct 2013
Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth.
J Clin Endocrinol MetabPihoker C, Gilliam LK, Ellard S, Dabelea D, Davis C, Dolan LM, Greenbaum CJ, Imperatore G, Lawrence JM, Marcovina SM, Mayer-Davis E, Rodriguez BL, Steck AK, Williams DE, Hattersley AT, SEARCH for Diabetes in Youth Study Group. -
Aug 2013
Use of a "fuzzy logic" controller in a closed-loop artificial pancreas.
Diabetes Technol TherMauseth R, Hirsch IB, Bollyky J, Kircher R, Matheson D, Sanda S, Greenbaum CJ -
Jun 2013
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
LancetMoran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Canakinumab Study Group., Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T, AIDA Study Group. -
Jun 2013
A SNP in G6PC2 predicts insulin secretion in type 1 diabetes.
Acta DiabetolSanda S, Wei S, Rue T, Shilling H, Greenbaum CJ -
Jun 2013
Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes.
Clin Exp ImmunolBollyky JB, Long SA, Fitch M, Bollyky PL, Rieck M, Rogers R, Samuels PL, Sanda S, Buckner JH, Hellerstein MK, Greenbaum CJ -
Jun 2013
Response to Comment on: Greenbaum et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 2012;61:2066-2073.
DiabetesGreenbaum CJ, Beam CA, Type 1 Diabetes TrialNet Study Group. -
Mar 2013
CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitoring.
ImmunologyYang J, James EA, Sanda S, Greenbaum CJ, Kwok WW -
Jan 2013
The influence of exposure to maternal diabetes in utero on the rate of decline in β-cell function among youth with diabetes.
J Pediatr Endocrinol MetabCrume TL, Andrews JS, D'Agostino RB Jr, Pettitt DJ, Mayer-Davis EJ, Law JR, Dolan L, Lawrence JM, Saydah S, Greenbaum CJ, Rodriguez BL, Dabelea DM, SEARCH for Diabetes in Youth Study Group. -
Dec 2012
Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study.
DiabetologiaDabelea D, Mayer-Davis EJ, Andrews JS, Dolan LM, Pihoker C, Hamman RF, Greenbaum CJ, Marcovina SM, Fujimoto W, Linder B, Imperatore G, D'Agostino R Jr -
Sep 2012
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.
DiabetesLong SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ, Diabetes TrialNet and the Immune Tolerance Network. -
Aug 2012
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.
DiabetesGreenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM, Type 1 Diabetes TrialNet Study Group. -
Jul 2012
The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes.
Diabetes CareSosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, Type 1 Diabetes TrialNet Study Group., Diabetes Prevention Trial-Type 1 Study Group. -
Jul 2012
Improvement in outcomes of clinical islet transplantation: 1999-2010.
Diabetes CareBarton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, Odorico JS, Garfinkel MR, Levy M, Pattou F, Berney T, Secchi A, Messinger S, Senior PA, Maffi P, Posselt A, Stock PG, Kaufman DB, Luo X, Kandeel F, Cagliero E, Turgeon NA, Witkowski P, Naji A, O'Connell PJ, Greenbaum CJ, Kudva YC, Brayman KL, Aull MJ, Larsen C, Kay TWH, Fernandez LA, Vantyghem MC, Bellin MD, Shapiro AMJ
